Fox Chase Cancer Center News

Fox Chase Study Finds That Non-Hispanic Black Patients With Locally Advanced Rectal Cancer Have Less Favorable Outcomes

PHILADELPHIA (February 29, 2024) — While sociodemographic, clinical, and pathological factors may affect racial and ethnic disparities in outcomes of patients with locally advanced rectal cancer, non-Hispanic Black patients consistently saw less favorable treatment outcomes independent of those factors, according to a study from researchers at Fox Chase Cancer Center published today.
VIEW STORY

Made With Love: Fox Chase Nurses Serve Valentine-Themed Dinners to Cancer Patients and Families

PHILADELPHIA (February 28, 2024) – With 65 guests and infinite kindness, members of the Nursing Professional Development Council and the Department of Nursing of Fox Chase Cancer Center hosted “That’s Amore!,” on Tuesday, February 13. This Valentine-themed dinner featured a host of Italian delights and brought together cancer patients and their families staying at Hope Lodge.
VIEW STORY

Psychological Distress Found as Both a Contributor to and Consequence of Cancer Treatment Delay

PHILADELPHIA (February 23, 2024) — Prior research has shown that delays in initiating cancer therapy are increasing, and these delays can lead to not only worse outcomes for patients, but also increased psychological distress. However, a new study published by researchers at Fox Chase Cancer Center has found that patients’ worry and fear can also contribute to their intentionally delaying the start of treatment.
VIEW STORY

Fox Chase Researcher Finds Genetic Differences in Rare Kidney Cancer Subtype That Could Lead to More Effective Treatment

PHILADELPHIA (February 22, 2024) — TFE3-rearranged renal cell carcinoma (rRCC) is a rare subtype of kidney cancer that can be misdiagnosed. This can affect treatment decisions and lead to patients receiving the wrong type of treatment. Now, a recently published study by scientists at Fox Chase Cancer Center identifies key genetic markers that can be used to distinguish rRCC from other cancers and also confirms which therapies are likely to be most effective. 
VIEW STORY

Fox Chase Researchers Find Oral Vancomycin Prevents C. Diff Infection in Stem Cell Transplant Recipients but Raises Risk of Gram-Negative Bacteremia

PHILADELPHIA (February 19, 2024) — Stem cell transplant recipients can reduce their risk of Clostridioides difficile (C. diff) infection by taking the oral antibiotic vancomycin preventively, according to research from Fox Chase Cancer Center presented at a scientific meeting. However, the study also shows that taking this antibiotic can increase these patients’ risk of gram-negative bacteremia.
VIEW STORY

Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute Physician Joshua Cohn to Serve as Consultant to Shriners Children’s Philadelphia

PHILADELPHIA (February 13, 2024) — As part of a recently announced collaboration, Joshua Cohn, MD, FPMRS, an Associate Professor in the Department of Urology at Fox Chase Cancer Center and a member of the Fox Chase – Temple Urologic Institute, will serve as a consultant at Shriners Children’s Philadelphia. He will care for patients with neurogenic urologic conditions, in which a patient lacks bladder control due to injury, neurological disorders, or congenital malformations.
VIEW STORY